MedTrace Logo

Study for Prevent Chronification Migraine Through Prediction of Response to Treatment With Anti-CGRP Antibodies

NCT06459648 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 350

Last updated 2025-09-24

No results posted yet for this study

Summary

Being able to predict each patients response to a specific treatment can mean a significant improvement in socioeconomic costs, but above all in their quality of life. With the present study, the investigators aim to analyze in a combined way different clinical, biological and neuroimaging variables, which allow the clinical staff to anticipate the response to treatment with anti-CGRP monoclonal antibodies in patients with migraine.

Conditions

Interventions

OTHER

Headache record

The patient will keep a record of the presence/absence of headache, average intensity, and need for acute medication.

OTHER

Scales

Each patient performs different scales that measure the impact of the migraine on their daily life as well as the disability it may be causing. In turn, each patient performs different scales that measure associated comorbidities such as depression, anxiety or insomnia.

DRUG

Monoclonal antibody anti-CGRP

Erenumab, Galcenazumeb, Fremanezumab, Eptinezumab

Sponsors & Collaborators

  • Fundación de Investigación Biomédica - Hospital Universitario de La Princesa

    lead OTHER

Principal Investigators

  • Ana Beatriz Gago Veiga · Fundación de Investigación Biomédica - Hospital Universitario de La Princesa

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-04-26
Primary Completion
2025-12-31
Completion
2025-12-31
FDA Drug
Yes

Countries

  • Spain

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06459648 on ClinicalTrials.gov